Stock Price Quote

HESTER BIOSCIENCES LTD.

NSE : HESTERBIOBSE : 524669ISIN CODE : INE782E01017Industry : Pharmaceuticals & DrugsHouse : Private
BSE1450.450.45 (+0.03 %)
PREV CLOSE ( ) 1450.00
OPEN PRICE ( ) 1460.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 77
TODAY'S LOW / HIGH ( )1422.80 1478.00
52 WK LOW / HIGH ( )1250.95 2347.7
NSE1450.80-3.8 (-0.26 %)
PREV CLOSE( ) 1454.60
OPEN PRICE ( ) 1454.60
BID PRICE (QTY) 1444.40 (1)
OFFER PRICE (QTY) 1459.00 (7)
VOLUME 1647
TODAY'S LOW / HIGH( ) 1421.00 1485.00
52 WK LOW / HIGH ( )1239.3 2350
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1987
Management Info
Bhupendra Gandhi - Chairman Rajiv Gandhi - Managing Director
Registered Office

Address Meda Adraj , Kadi, , ,
Mehsana,
Gujarat-384441

Phone 079 – 26445106

Email mail@hester.in

Website www.hester.in

Registrars Details
MUFG Intime India Pvt Ltd.
506-508, 5th Floor, Amaranth Business Complex - I (ABC - I),Beside Gala Business Center, St. Xaviers Corner, Off C.G. Road,Navrangpura,Ahmedabad
Listing : BSE, NSE

NEWS

08Apr Hester Biosciences informs about compl
Hester Biosciences has informed that the details of securities demateria..
11Mar Hester Biosciences gets nod to divest
Hester Biosciences has received approval for the divestment of 43.81% eq..
11Mar Hester Biosciences informs about outco
Hester Biosciences has informed that the Board of Directors at the meeti..
05Feb Hester Biosciences informs about board
Hester Biosciences has informed that it submitted a newspaper clipping o..
02Feb Hester Biosciences informs about confe
Hester Biosciences has informed that it enclosed the transcript of the e..

Financials

in Millions
QTR Dec 25 ANNUAL 25
Net Profit106.69318.42
Gross Profit 146.42 417.6
Operating Profit 177.51557.08
Net Sales 703.542864.66

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Astrazeneca Pharma I (BSE)
peergroup  8718.05 (5.14%)
M.Cap ( in Cr)21795.13
Onesource Specialty (BSE)
peergroup  1543.30 (7.37%)
M.Cap ( in Cr)17692.80
Ajanta Pharma (BSE)
peergroup  2895.85 (3.29%)
M.Cap ( in Cr)36179.48
Venus Remedies (BSE)
peergroup  1039.95 (4.61%)
M.Cap ( in Cr)1390.10
Glenmark Pharma (BSE)
peergroup  2194.05 (1.44%)
M.Cap ( in Cr)61916.27

Shareholding Pattern

PROMOTERS 53.73%
NON-INSTITUTION 45.89%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Hester Biosciences Ltd.

Hester Biosciences Ltd. was incorporated in the year 1987. Its today's share price is 1450.45. Its current market capitalisation stands at Rs 1233.88 Cr. In the latest quarter, company has reported Gross Sales of Rs. 2866.36 Cr and Total Income of Rs.2912.3 Cr. The company's management includes Vinod Mali, Jatin Trivedi, Anil Jain, Ameet Desai, Ashok Bhadakal, Sandhya Patel, Nina Gandhi, Ravin Gandhi, Sanjiv Gandhi, Priya Gandhi, Rajiv Gandhi, Bhupendra Gandhi.

It is listed on the BSE with a BSE Code of 524669 , NSE with an NSE Symbol of HESTERBIO and ISIN of INE782E01017. It's Registered office is at Meda Adraj , Kadi, , Mehsana-384441, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Apaji Amin & Co LLP, Chandulal M Shah & Co, Shah Karia & Associates, Shah Narielwala & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.